Nuclear Receptor Resource
  • Home
  • Nuclear Receptors
  • Education
    • General Information
    • Drawings
    • White Papers
    • New Publications
    • Other Resources
    • Newsletter Archive
  • About
    • About NRR
    • About the Editor
    • Sponsor
  • Contact
    • Contact NRR
Select Page

Discovery of Retinoic Acid-Related Orphan Receptor γt Inverse Agonists via Docking and Negative Image-Based Screening

by Marketing | Jun 11, 2018 | New Publications

ABSTRACT Retinoic acid-related orphan receptor γt (RORγt) has a vital role in the differentiation of T-helper 17 (TH17) cells. Potent and specific RORγt inverse agonists are sought for treating TH17-related diseases such as psoriasis, rheumatoid arthritis, and type 1...

Bitter melon seed oil increases mitochondrial content in gastrocnemius muscle and improves running endurance in sedentary C57BL/6 J mice

by Marketing | Jun 6, 2018 | New Publications

ABSTRACT The α-eleostearic acid (α-ESA) in bitter melon seed oil (BMSO) is efficiently converted by the body into rumenic acid. The objective of this study was to investigate effects of BMSO on skeletal muscle fiber-type switch and endurance capacity in mice, with or...

A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions

by Marketing | May 9, 2018 | New Publications

ABSTRACT Estrogen receptor-beta (ERβ) is a drug target for memory consolidation in postmenopausal women. Herein is reported a series of potent and selective ERβ agonists (SERBAs) with in vivo efficacy that are A–C estrogens, lacking the B and D estrogen rings. The...

Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions

by Marketing | Apr 5, 2018 | New Publications

ABSTRACT Small molecule agonism of PPARα represents a promising new avenue for the development of non-invasive treatments for oculovascular diseases like diabetic retinopathy and age-related macular degeneration. Herein we report initial structure–activity...

Pyrazolone Compounds and Uses Thereof: Patent Application

by Marketing | Mar 22, 2018 | New Publications

ABSTRACT The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid...
« Older Entries

Sponsored By

Indigo_Logo_4color INDIGO Biosciences, industry-leading provider of both products and services focused on nuclear receptors.

Join the Mailing List

Sign up to join INDIGO Biosciences mailing list.

Sign Up!

About this site

This website utilizes a wide variety of external resources and databases. This optimizes the simplicity in keeping up-to-date, but it decreases the amount that is "personalized" by the editors of this site, and by you the visitor. Please, take time to add to the weblog or to contact the NRR. We are always looking for contributions, suggestion and words of encouragement

Editor-in-Chief

Jack Vanden Heuvel, PhD
Professor of Molecular Toxicology
Penn State University
Disclaimer: Dr. Vanden Heuvel is CSO of INDIGO Biosciences Inc. and is compensated for his activity.
NRR Nuclear Receptor Resource


© 2016 Nuclear Receptor Resource.
All Rights Reserved